At the 2017 American Society of Hematology Meeting promising data were presented reflecting the impressing advances of clinical research in multiple myeloma. In fit patients eligible for autologous stem cell transplantation new induction regimens showed high response and minimal residual disease negativity rates. Again the important role of autologous stem cell transplantation was pointed out especially for patients with high risk cytogenetics. In the relapsed setting intensified combination therapies are related with improvement of PFS (progression free survival) and even OS (overall survival). Concerning maintenance therapy significant benefits in all standard, high and ultra-high risk groups of patients could be demonstrated. New developements like Selinexor, Filanesib and CAR (chimeric antigen receptor) T cells showed impressing results in a heavily pretreated population.